<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-6 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-6</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-6</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of the duration of anti-PD1 immunotherapy in melanoma, including how duration relates to degree of response (e.g., complete response, partial response, stable disease), criteria for discontinuation, outcomes by duration and response, and any recommendations or guidelines regarding optimal duration.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Type of study (e.g., randomized controlled trial, retrospective cohort, meta-analysis, guideline, expert opinion).</td>
                    </tr>
                    <tr>
                        <td><strong>population_description</strong></td>
                        <td>str</td>
                        <td>Description of the patient population (e.g., stage of melanoma, prior treatments, number of patients).</td>
                    </tr>
                    <tr>
                        <td><strong>anti_pd1_agent</strong></td>
                        <td>str</td>
                        <td>Name(s) of the anti-PD1 agent(s) used (e.g., pembrolizumab, nivolumab).</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_duration_reported</strong></td>
                        <td>str</td>
                        <td>Reported duration of anti-PD1 therapy (e.g., planned duration, median duration, range, fixed vs. indefinite, duration until response, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>discontinuation_criteria</strong></td>
                        <td>str</td>
                        <td>Criteria for discontinuation of therapy (e.g., after complete response, after 1 or 2 years, due to toxicity, patient choice, progression, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>response_category</strong></td>
                        <td>str</td>
                        <td>Degree of response reported (e.g., complete response, partial response, stable disease, progressive disease).</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_by_duration_and_response</strong></td>
                        <td>str</td>
                        <td>Key outcomes reported by duration and response category (e.g., recurrence-free survival, overall survival, progression-free survival, relapse rates after discontinuation, etc.; include numerical values and timepoints if available).</td>
                    </tr>
                    <tr>
                        <td><strong>adverse_events_by_duration</strong></td>
                        <td>str</td>
                        <td>Adverse events or toxicity reported in relation to duration of therapy (e.g., increased toxicity with longer duration, late-onset toxicity, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>comparison_groups</strong></td>
                        <td>str</td>
                        <td>Description of any comparison groups (e.g., fixed duration vs. indefinite, early discontinuation vs. standard, by response category, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>recommendations_or_guidelines</strong></td>
                        <td>str</td>
                        <td>Any recommendations, guidelines, or expert consensus statements regarding optimal duration of anti-PD1 therapy in melanoma, especially as it relates to degree of response.</td>
                    </tr>
                    <tr>
                        <td><strong>evidence_for_different_durations_by_response</strong></td>
                        <td>str</td>
                        <td>Summary of evidence supporting or refuting different durations of therapy based on degree of response (e.g., is shorter duration safe in complete responders?).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>